{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T05:55:47Z","timestamp":1775195747770,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100012297","name":"Society of Family Planning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012297","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","contraceptionjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.contraception.2020.04.019","type":"journal-article","created":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T04:31:39Z","timestamp":1588825899000},"page":"174-179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Etonogestrel concentrations among contraceptive implant users in Botswana using and not using dolutegravir-based antiretroviral therapy"],"prefix":"10.1016","volume":"102","author":[{"given":"Ian J.","family":"Bishop","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8025-3793","authenticated-orcid":false,"given":"Alida M.","family":"Gertz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boikhutso","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leabaneng","family":"Tawe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwana","family":"Lechiile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Teodoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aamirah","family":"Mussa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ava","family":"Avalos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sifelani","family":"Malima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tshego","family":"Maotwe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lesego","family":"Mokganya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn L.","family":"Westhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chelsea","family":"Morroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2020.04.019_b0005","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s10461-018-2346-4","article-title":"Unintended pregnancy in women living with HIV in Sub-Saharan Africa: a systematic review and meta-analysis","volume":"23","author":"Feyissa","year":"2019","journal-title":"AIDS Behav"},{"key":"10.1016\/j.contraception.2020.04.019_b0010","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12913-018-2942-z","article-title":"High rate of unplanned pregnancy in the context of integrated family planning and HIV care services in South Africa","volume":"18","author":"Adeniyi","year":"2018","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.contraception.2020.04.019_b0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197216","article-title":"Unplanned pregnancies and contraceptive use among HIV-positive women in care","volume":"13","author":"Sutton","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.contraception.2020.04.019_b0020","unstructured":"UNAIDS. 19.6 million girls and women living with HIV 2019. https:\/\/www.unaids.org\/en\/resources\/infographics\/girls-and-women-living-with-HIV (accessed March 16, 2020)."},{"key":"10.1016\/j.contraception.2020.04.019_b0025","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/01.olq.0000194602.01058.e1","article-title":"The value of contraception to prevent perinatal HIV transmission","volume":"33","author":"Reynolds","year":"2006","journal-title":"Sex Transm Dis"},{"issue":"Suppl 2","key":"10.1016\/j.contraception.2020.04.019_b0030","doi-asserted-by":"crossref","first-page":"ii49","DOI":"10.1136\/sti.2008.030049","article-title":"Contraception to prevent HIV-positive births: current contribution and potential cost savings in PEPFAR countries","volume":"84","author":"Reynolds","year":"2008","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.contraception.2020.04.019_b0035","unstructured":"IATT M&E WG. Global Monitoring Framework and Strategy for the Global Plan towards elimination of new HIV infections among children by 2015 and keeping their mothers alive (EMTCT) 2012. http:\/\/srhhivlinkages.org\/wp-content\/uploads\/2013\/04\/global_plan_me_frame_en.pdf (accessed March 16, 2020)."},{"key":"10.1016\/j.contraception.2020.04.019_b0040","doi-asserted-by":"crossref","first-page":"72","DOI":"10.9745\/GHSP-D-13-00116","article-title":"Scaling up delivery of contraceptive implants in sub-Saharan Africa: operational experiences of Marie Stopes International","volume":"2","author":"Duvall","year":"2014","journal-title":"Glob Heal Sci Pract"},{"key":"10.1016\/j.contraception.2020.04.019_b0045","doi-asserted-by":"crossref","first-page":"17","DOI":"10.9745\/GHSP-D-17-00396","article-title":"Liftoff: the blossoming of contraceptive implant use in Africa","volume":"6","author":"Jacobstein","year":"2018","journal-title":"Glob Heal Sci Pract"},{"key":"10.1016\/j.contraception.2020.04.019_b0050","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1097\/QAD.0000000000001591","article-title":"Efavirenz decreases etonogestrel exposure: a pharmacokinetic evaluation of implantable contraception with antiretroviral therapy","volume":"31","author":"Chappell","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.contraception.2020.04.019_b0055","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/QAI.0000000000000189","article-title":"Effect of antiretroviral therapy including lopinavir\/ritonavir or efavirenz on etonogestrel-releasing implant pharmacokinetics in HIV-positive women","volume":"66","author":"Vieira","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.contraception.2020.04.019_b0060","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1097\/QAD.0000000000000177","article-title":"Implementing the Jadelle implant for women living with HIV in a resource-limited setting: concerns for drug interactions leading to unintended pregnancies","volume":"28","author":"Perry","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.contraception.2020.04.019_b0065","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2352-3018(15)00184-8","article-title":"Pregnancy rates in HIV-positive women using contraceptives and efavirenz-based or nevirapine-based antiretroviral therapy in Kenya: a retrospective cohort study","volume":"2","author":"Patel","year":"2015","journal-title":"Lancet HIV"},{"key":"10.1016\/j.contraception.2020.04.019_b0070","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/cid\/civ1001","article-title":"Unintended pregnancies observed with combined use of the levonorgestrel contraceptive implant and efavirenz-based antiretroviral therapy: a three-arm pharmacokinetic evaluation over 48 weeks","volume":"62","author":"Scarsi","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.contraception.2020.04.019_b0075","unstructured":"WHO. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infections. Recommendations for a Public Health Approach n.d. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/208825\/9789241549684_eng.pdf?sequence=1 (accessed March 16, 2020)."},{"key":"10.1016\/j.contraception.2020.04.019_b0080","unstructured":"WHO. Update of recommendations on first- and second-line antiretroviral regimens. 2019 n.d. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/325892\/WHO-CDS-HIV-19.15-eng.pdf?ua=1 (accessed March 16, 2020)."},{"key":"10.1016\/j.contraception.2020.04.019_b0085","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.1016\/S2352-3018(19)30400-X","article-title":"Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines","volume":"7","author":"Phillips","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.contraception.2020.04.019_b0090","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1124\/dmd.112.048918","article-title":"In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor","volume":"41","author":"Reese","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.contraception.2020.04.019_b0095","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s40264-016-0452-7","article-title":"Drug-drug interactions, effectiveness, and safety of hormonal contraceptives in women living with HIV","volume":"39","author":"Scarsi","year":"2016","journal-title":"Drug Saf"},{"key":"10.1016\/j.contraception.2020.04.019_b0100","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1056\/NEJMc1807653","article-title":"Neural-tube defects with dolutegravir treatment from the time of conception","volume":"379","author":"Zash","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.contraception.2020.04.019_b0105","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/0010-7824(91)90030-J","article-title":"Clinical trial with 3-keto-desogestrel subdermal implants","volume":"44","author":"Diaz","year":"1991","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2020.04.019_b0110","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/FTD.0b013e31829a10fa","article-title":"A UPLC-MS\/MS method for therapeutic drug monitoring of etonogestrel","volume":"35","author":"Thomas","year":"2013","journal-title":"Ther Drug Monit"},{"issue":"Suppl 2","key":"10.1016\/j.contraception.2020.04.019_b0115","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1080\/14730782.2000.12288981","article-title":"The pharmacokinetics and pharmacodynamics of Implanon, a single-rod etonogestrel contraceptive implant","volume":"5","author":"Coelingh-Bennink","year":"2000","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2020.04.019_b0120","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1177\/1060028015580637","article-title":"Dolutegravir has no effect on the pharmacokinetics of oral contraceptives with norgestimate and ethinyl estradiol","volume":"49","author":"Song","year":"2015","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.contraception.2020.04.019_b0125","unstructured":"Patel RC, Stalter R, Onono M, Brown E, Adeojo LW, Kidiga Adhu C, Bukusi EA, Scarsi KK. Dolutegravir-containing ART does not reduce etonogestrel implant concentrations. Boston, USA: Conference on Retroviruses and Opportunistic Infections (CROI); 8\u201311 March 2020."},{"key":"10.1016\/j.contraception.2020.04.019_b0130","doi-asserted-by":"crossref","first-page":"e601","DOI":"10.1016\/S2352-3018(19)30155-9","article-title":"Antiretroviral therapy and vaginally administered contraceptive hormones: a three-arm, pharmacokinetic study","volume":"6","author":"Scarsi","year":"2019","journal-title":"Lancet HIV"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782420301347?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782420301347?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T20:16:50Z","timestamp":1757881010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782420301347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0010782420301347"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2020.04.019","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Etonogestrel concentrations among contraceptive implant users in Botswana using and not using dolutegravir-based antiretroviral therapy","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2020.04.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}